Arrevus

Novel Anti-Infectives from Natural Selection

Insects are products of millions of years of natural selection. They have faced countless bacterial pathogens, many of which are the same pathogens that infect humans. As a result, insects have developed fast-acting antibacterial immunity crucial to their survival. Arrevus is modifying these insect-derived molecules to create a new class of therapeutic agents.

Arrevus is committed to creating a new class of therapeutics for immunocompromised populations.

Insects have developed unique compounds for combating bacterial pathogens. Our Insect Derived Anti-Infective (IDEA) platform enables new therapy development based on these molecules, expanding our therapeutic pipeline.

We use targeted therapeutics created from our IDEA platform to impact serious infections based on their natural histories. These therapies are developed to improve the clinical outcomes in patients with ineffective immune responses to serious infections.